Search Results

Cyclerion Therapeutics, Inc. today announced that Regina Graul, Ph.D., has joined the company as president, effective immediately.

Cyclerion Therapeutics, Inc., a biopharmaceutical company on a mission to develop treatments for serious diseases, announced the appointments of Dina Katabi, Ph.D., and Michael Higgins to its Board of Directors.

Cyclerion Therapeutics, Inc. announced that it has received a formal notice from The Nasdaq Stock Market stating that Cyclerion has regained compliance with the $1.00 per share minimum bid price requirement pursuant to Nasdaq Listing Rule 5550, and that Cyclerion is in compliance with all applicable listing standards.

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced corporate updates and first quarter 2023 financial results.

Cyclerion Therapeutics, Inc. announced that it has signed a definitive agreement with a new private company to sell two of its sGC stimulator assets in exchange for cash and equity ownership.

Cyclerion Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to zagociguat (previously CY6463) for the treatment of mitochondrial diseases.

Cyclerion Therapeutics, Inc. announced that the Board of Directors of the Company, acting solely by all of its independent and disinterested members, has reviewed a non-binding proposal received on March 17, 2023 from an entity formed by investors that include the Company’s Chief Executive Officer, to purchase the Company’s zagociguat and CY3018 assets.